Possible environmental, occupational, and other etiologic factors for Parkinson's disease: A case-control study in Germany

Neurology

Volumn 46, Issue 5, 1996, Pages 1275-1284

  Seidler, A ^a   Hellenbrand, W ^b   Robra, B P ^b   Vieregge, P ^c   Nischan, P ^a   Joerg, J ^d   Oertel, W H ^e   Ulm, G ^f   Schneider, E ^g  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

^d Barmen Hospital   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f Paracelsus Elena Hospital   (Germany)

^g Asklepios Klinik Harburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; HEAVY METAL; HERBICIDE; NEUROTOXIN; PESTICIDE; SOLVENT; WOOD PROTECTING AGENT;

ADULT; AGED; AGRICULTURAL WORKER; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; EDUCATION; ENVIRONMENTAL FACTOR; EXHAUST GAS; FEMALE; GENERAL ANESTHESIA; GERMANY; HEAD INJURY; HEREDITY; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; PARKINSON DISEASE; PREMATURE LABOR; PRIORITY JOURNAL; RURAL AREA; SMOKING;

EID: 0030012558     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.46.5.1275     Document Type: Article

References (96)

1. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
2. 18F]Dopa positron emission tomography studies in an Irish kindred. Ann Neurol 1992;32:609-617.
3. Golbe LI, Miller DG, Duvoisin RC. Autosomal dominant Lewy-body Parkinson's disease. Adv Neurol 1990;53:287-292.
4. Burn DJ, Mark MH, Playford ED, et al. Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology 1992;42:1894-1900.
5. Vieregge P, Schiffke KA, Friedrich HJ, Müller B, Ludin HP. Parkinson's disease in twins. Neurology 1992;42:1453-1461.
6. Vieregge P. Genetic factors in the etiology of idiopathic Parkinson's disease. J Neural Transm 1994;8:1-37.
7. Kurth JH, Kurth MC, Poduslo SE, Schwankhaus JD. Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol 1993;33:368-372.
8. Barbeau A, Cloutier T, Roy M, Plassé L, Paris S, Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 1985;2:1213-1216.
9. Barbeau A, Roy M, Cloutier T, Plassé L, Paris S. Environmental and genetic factors in the etiology of Parkinson's disease. Adv Neurol 1986;45:299-306.
10. Smith CAD, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992;339:1375-1377.
11. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992;339:1017-1018.
12. Kondo I, Kanazawa I. Debrisoquine hydroxylase and Parkinson's disease. Adv Neurol 1993;60:338-342.
13. Steventon GB, Heafield MTE, Waring RH, Williams AC. Xenobiotic metabolism in Parkinson's disease. Neurology 1989; 39:883-887.
14. Waring RH, Steventon GB, Sturman SG, Heafield MTE, Smith MCG, Williams AC. S-methylation in motorneuron disease and Parkinson's disease. Lancet 1989;2:356-357.
15. Johnson WG, Hodge SE, Duvoisin R. Twin studies and the genetics of Parkinson's disease - a reappraisal. Mov Disord 1990;5:187-194.
16. Kondo K, Kurland LT, Schull WJ. Parkinson's disease. Genetic analysis and evidence of a multifactorial etiology. Mayo Clinic Proc 1973;48:465-475.
17. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine. Life Sci 1985;36:2503-2508.
18. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-389.
19. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32: 804-812.
20. Jenner P. Oxidative stress as a cause of Parkinson's disease. Acta Neurol Scand 1991;84(suppl 36):6-15.
21. Jenner P, Dexter DT, Sian J, Schapira AHV, Marsden CD. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann Neurol 1992; 32:S82-S87.
22. Riederer P, Sofic E, Rausch W-D, et al. Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515-520.
23. Saggu H, Cooksey J, Dexter D, et al. A selective increase in particulate Superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 1989;53:692-697.
24. Olanow CW. A radical hypothesis for radical degeneration. Trends Neurosci 1993;16:439-444.
25. Vieregge P, von Maravic C, Friedrich H-J. Life-style and dietary factors early and late in Parkinson's disease. Can J Neurol Sci 1992;19:170-173.
26. Golbe LI, Farrell TM, Davis PH. Follow-up study of early-life protective and risk factors in Parkinson's disease. Mov Disord 1990;5:66-70.
27. Koller W, Vetere-Oldfield B, Gray C, et al. Environmental risk factors in Parkinson's disease. Neurology 1990;40:1218-1221.
28. Ho SC, Woo J, Lee CM. Epidemiologic study of Parkinson's disease in Hong Kong. Neurology 1989;39:1314-1318.
29. Jiménez-Jiménez FJ, Mateo D, Gimenez-Roldan S. Exposure to well water and pesticides in Parkinson's disease: a case-control study in the Madrid area. Mov Disord 1992;7:149-152.
30. Wong GF, Gray CS, Hassanein RS, Koller WC. Environmental risk factors in siblings with Parkinson's disease. Arch Neurol 1991;48:287-289.
31. Hertzman C, Wiens M, Bowering D, Snow B, Calne D. Parkinson's disease: a case-control study of occupational and environmental risk factors. Am J Indust Med 1990;17:349-355.
32. Rajput AH, Uitti RJ, Stern W, Laverty W. Early onset Parkinson's disease and childhood environment. Adv Neurol 1986;45: 295-297.
33. Semchuk KM, Love EJ, Lee RG. Parkinson's disease and exposure to rural environmental factors: a population-based case-control study. Can J Neurol Sci 1991;18:279-286.
34. Semchuk KM, Love EJ, Lee RG. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 1992;42:1328-1335.
35. Stern M, Dulaney E, Gruber SB, et al. The epidemiology of Parkinson's disease: a case-control study of young-onset and old-onset patients. Arch Neurol 1991;48:903-907.
36. Calne S, Schoenberg B, Martin W, Uitti RJ, Spencer P, Calne DB. Familial Parkinson's disease: possible role of environmental factors. Can J Neurol Sci 1987;14:303-307.
37. Wang W, Fang X, Cheng X, Jiang D, Lin Z. A case-control study on the environmental risk factors of Parkinson's disease in Tianjin, China. Neuroepidemiology 1993;12:209-218.
38. Tanner CM, Chen B, Peng M, et al. Environmental factors and Parkinson's disease: a case-control study in China. Neurology 1989;39:660-664.
39. Zayed J, Ducic S, Campanella G, et al. Facteurs environnementeaux dans la maladie de Parkinson. Can J Neurol Sci 1990;17:286-291.
40. Hart TB. Parkinson's disease and pesticides. Lancet 1987;1: 38.
41. Koller WC. Paraquat and Parkinson's disease [letter]. Neurology 1986;36:1147.
42. Perry TL, Yong VW, Wall RA, Jones K. Paraquat and two endogenous analogues of the neurotoxic substance MPTP do not damage dopaminergic nigrostriatal neurons in the mouse. Neurosci Lett 1986;69:285-289.
43. Sanchez-Ramos JR, Hefti F, Weiner WJ. Paraquat and Parkinson's disease. Neurology 1987;37:728.
44. Hertzman C, Wiens M, Snow B, Kelly S, Calne D. A case-control study of Parkinson's disease in a horticultural region of British Columbia. Mov Disord 1994;9:69-75.
45. Ohlson C-G, Hogstedt C. Parkinson's disease and occupational exposure to organic solvents, agricultural chemicals and mercury - a case-referent study. Scand J Work Environ Health 1981;7:252-256.
46. Ngim CH, Devathasan G. Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson's disease. Neuroepidemiology 1989;8:128-141.
47. Kahn HA. The Dorn study of smoking and mortality among US veterans. Report on eight and one-half years of observation. Natl Cancer Inst Monogr 1966;19:1-125.
48. Rogot E, Murray JL. Smoking and causes of death among U.S. veterans: 16 years of observation. Public Health Rep 1980;95: 213-222.
49. Hammond EC. Smoking in relation to the death rates of one million men and women. Natl Cancer Inst Monogr 1966;19: 127-204.
50. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. BMJ 1976;2:1525-1536.
51. Grandinetti A, Morens DM, Reed D, MacEachern D. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol 1994;139: 1129-1138.
52. Nefzger MD, Quadfasel FA, Karl VC. A retrospective study of smoking in Parkinson's disease. Am J Epidemiol 1968;88: 149-158.
53. Kessler II, Diamond EL. Epidemiologic studies of Parkinson's disease. I. Smoking and Parkinson's disease: a survey and explanatory hypothesis. Am J Epidemiol 1971;94:16-25.
54. Kessler II. Epidemiologic studies of Parkinson's disease. III. A community-based survey. Am J Epidemiol 1972;96:242-254.
55. Baumann RJ, Jameson HD, McKean HE, Haack DG, Weisberg LM. Cigarette smoking and Parkinson's disease. 1. A comparison of cases with matched neighbours. Neurology 1980;30:839-843.
56. Marttila RJ, Rinne UK. Smoking and Parkinson's disease. Acta Neurol Scand 1980;62:322-325.
57. Haack DG, Baumann RJ, McKean HE, Jameson HD, Turbek JA. Nicotine exposure and Parkinson disease. Am J Epidemiol 1981;114:191-200.
58. Godwin-Austen RB, Lee PN, Marmot MG, Stern GM. Smoking and Parkinson's disease. J Neurol Neurosurg Psychiatry 1982;45:577-581.
59. Bharucha NE, Stokes L, Schoenberg BS, et al. A case-control study of twin pairs discordant for Parkinson's disease: a search for environmental risk factors. Neurology 1986;36: 284-288.
60. Cazzati G, Capus L, Monti F, Carraro N. Abitudine al fumo e morbo di Parkinson. Riv Neurol (Napoli) 1985;55:79-87.
61. Hofman A, Collette HJA, Barteids AIM. Incidence and risk factors of Parkinson's disease in the Netherlands. Neuroepidemiol 1989;8:296-299.
62. Vieregge P, Friedrich HJ, Rohl A, Ulm G, Heberlein I. Zur multifaktoriellen Ätiologie der idiopathischen Parkinson-Krankheit. Eine Fall-Kontroll-Studie. Nervenarzt 1994;65: 390-395.
63. Mayeux R, Tang MX, Marder K, Coté LJ, Stern Y. Smoking and Parkinson's disease. MOV Disord 1994;9:207-212.
64. Rajput AH, Offord KP, Beard CM, Kurland LT. A case-control study of Smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease. Neurology 1987;37:226-232.
65. Hughes AJ, Daniel SE, Kilford L, Lees A. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathologic study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55: 181-184.
66. Jessen RJ. Statistical Survey techniques. New York: John Wiley and Sons, 1978.
67. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. Lyon: IARC Scientific Publication No. 32, International Agency for Research on Cancer, 1982.
68. Schlesselman JJ. Case-control studies. Design, conduct, analysis. Oxford: Oxford University Press, 1982.
69. Statistisches Bundesamt, Ed. Statistisches Jahrbuch 1993 für die Bundesrepublik Deutschland. Wiesbaden: Wiesbadener Graphische Betriebe GmbH, 1993.
70. Fleming L, Mann JB, Bean J, Briggle T, Sanchez-Ramos JR. Parkinson's disease and brain levels of organochlorine pesticides. Ann Neurol 1994;36:100-103.
71. Secchi GP, Angetti V, Piredda M, et al. Acute and persistent parkinsonism after use of diquat. Neurology 1992;42:261-263.
72. Eckrich W. Toxicology of wood preservatives. Lecture for the 4th session of the Committee for Environmental and Radiation Protection of the Medical Society of Baden-Württemberg. Engelskirchen, IHG e.V., 1989.
73. Jorens PG, Schepens PJ. Human pentachlorophenol poisoning. Hum Exp Toxicol 1993;12:479-495.
74. Semchuk KM, Love EJ, Lee RG. Parkinson's disease: a test of the multifactorial hypothesis. Neurology 1993;43:1173-1180.
75. Weiner JA, Nylander M, Berglund F. Does mercury from amalgam constitute a health hazard? Sci Total Environ 1990; 126:61-74.
76. Weiner JA, Nylander M. The relationship between mercury concentrations in human organs and different predictor variables. Sci Total Environ 1993;138:101-115.
77. Eggleston DW, Nylander M. Correlation of dental amalgam with mercury in brain tissue. J Prosthet Dent 1987;58:704-707.
78. Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52:1830-1836.
79. Yasui M, Kihira T, Ota K. Calcium, magnesium and aluminum concentrations in Parkinson's disease. Neurotoxicology 1992;13:593-600.
80. Bouyer J, Hémon D. Retrospective evaluation of occupational exposures in population-based case-control studies. General overview with special attention to job exposure matrices. Int J Epidemiol 1993;22(suppl 2):S57-S64.
81. Siemiatycki J, Dewar R, Richardson L. Costs and statistical power associated with five methods of collecting occupation exposure information for population-based case-control studies. Am J Epidemiol 1989;130:1236-1246.
82. Dewar R, Siemiatycki J, Gérin M. Loss of statistical power associated with the use of a job-exposure matrix in occupational case-control studies. Appl Occup Environ Hyg 1991;6: 508-515.
83. Ahrens W, Jöckel K-H, Brochard P, et al. Retrospective assessment of asbestos exposure. I. Case-control analysis in a study of lung cancer: efficiency of job-specific questionnaires and job-exposure matrices. Int J Epidemiol 1993;22(suppl 2): S83-S95.
84. Van Vliet C, Swaen GMH, Volovics A, et al. Exposure-outcome relationships between organic solvent exposure and neuropsychiatric disorders: results from a Dutch case-control study. Am J Ind Med 1989;16:707-718.
85. Reinvang I, Borchgrevink HM, Aaserud O, et al. Neuropsychological findings in a nonclinical sample of workers exposed to solvents. J Neurol Neurosurg Psychiatry 1994;57:614-616.
86. Gregerson P, Klausen H, Elsnab CU. Chronic toxic encephalopathy in solvent exposed painters in Denmark 1976-1980: clinical cases and social consequences after a 5-year follow-up. Am J Ind Med 1987;11:399-417.
87. Cherry NM, Labrèche FP, McDonald JC. Organic brain damage and occupational solvent exposure. Br J Ind Med 1992;49: 776-781.
88. Brackbill RM, Maizlish N, Fischbach T. Risk of neuropsychiatric disability among painters in the United States. Scand J Work Environ Health 1990;16:182-188.
89. Fuxe K, Andersson K, Nilsen OG, Toftgard R, Eneroth P, Gustafsson JA. Toluene and telencephalic dopamine: selective reduction of amine turnover in discrete DA nerve terminal systems of the anterior caudate nucleus by low concentrations of toluene. Toxicol Lett 1982;12:115-123.
90. Uitti RJ, Snow BJ, Shinotoh H, et al. Parkinsonism induced by solvent abuse. Ann Neurol 1994;35:616-619.
91. Factor SA, Sanchez-Ramos J, Weiner WJ. Trauma as an etiology of parkinsonism: a historical view of the concept. Mov Disord 1988;3:30-36.
92. Kontouris D, Gehlen W. Zum Problem des posttraumatischen Parkinson Syndroms. In: Gänshirt H, ed. Pathophysiologie, Klinik, und Therapie des Parkinsonismus. Basel: Editiones Roches, 1983;143-149.
93. Ward CD, Duvoisin R, Ince SE, Nutt JD, Eldridge R, Calne DB. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983;33:815-824.
94. Factor SA, Weiner WJ. Prior history of head trauma in Parkinson's disease. Mov Disord 1991;6:225-229.
95. Williams DB, Annegers JF, Kokmen E, O'Brien PC, Kurland LT. Brain injury and neurologic sequelae: a cohort study of dementia, parkinsonism, and amyotrophic lateral sclerosis. Neurology 1991;41:1554-1557.
96. Eldridge R, Ince SE. The low concordance rate for Parkinson's disease in twins: a possible explanation. Neurology 1984;34: 1354-1356.